Evidence map›Paper›PMID 42433291›Full record

ArticlebioRxiv : the preprint server for biology2026

DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.

J Richard Brewer, Ailin Han, Amin H Nassar, Elias Bou Farhat, Holly N Blackburn, Tianli Xiao, Haris Mirza, Walter K Mowel, Esen Sefik, Saskia Hartner and 25 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

J Richard BrewerDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Ailin HanDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Amin H NassarDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Elias Bou FarhatDivision of Pulmonary Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Holly N BlackburnDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Tianli XiaoDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Haris MirzaDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Walter K MowelDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Esen SefikDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Saskia HartnerDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Michael ChiorazziDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Takeshi ItoDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Min-Hee OhDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Matthew Z MaddenDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Athreya RangavajhulaDepartment of Immunobiology, Yale University, New Haven, CT, USA.
Elio AdibDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mustafa J SalehDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Marc MachaalaniDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mehrdad RakaeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Masoud TafavvoghiDepartment of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.
Claire QuattropaniYale Clinical Hematology, Yale New Haven Hospital, New Haven, CT, USA.
Nicole GazetosYale Clinical Hematology, Yale New Haven Hospital, New Haven, CT, USA.
David GerberDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Farjana FattahHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jeffrey A SoRelleDepartment of Pathology, Division of Genomic and Molecular Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Dominic ChooHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Mitchell S von ItzsteinDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shannon Bevans-FontiDivision of Pulmonary/Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.
Mohammad GhanbarDivision of Pulmonary/Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.
Karthik SureshDivision of Pulmonary/Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.
Thomas MazumderDivision of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Chun J YeDivision of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Alexander GusevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Richard A FlavellDepartment of Immunobiology, Yale University, New Haven, CT, USA.

Funding

INTERDISCIPLINARY IMMUNOLOGY TRAINING PROGRAMT32AI007019 · NIAID · YALE UNIVERSITY · PI Carrie L. Lucas, David G. Schatz · 1985 to 2026
$14.4M
Training Program in Investigative HepatologyT32DK007356 · NIDDK · YALE UNIVERSITY · PI MICHAEL H NATHANSON · 1986 to 2026
$7.4M
Investigation of Dpp9 in COVID19R21AI178249 · NIAID · YALE UNIVERSITY · PI FLAVELL, RICHARD A · 2023 to 2024
$454k
NIAID NIH HHS R21 AI178249NIAID NIH HHS T32 AI007019NIDDK NIH HHS T32 DK007356
6 · The paper itself

Abstract

Over one million patients receive cancer immunotherapy annually, yet the mechanisms underlying life-threatening immune-mediated toxicities remain poorly understood. Checkpoint inhibitor pneumonitis (CIP) is the leading cause of immunotherapy-related mortality, with a case fatality rate approaching 10%, and no genetic risk factors have been described to date. We identified Dipeptidyl-peptidase 9 (DPP9) as the first genetic susceptibility gene for CIP in a clinico-genomics cohort of 4,397 patients treated with immune checkpoint inhibitors. Mechanistically, DPP9 suppresses CARD8 inflammasome activation and IL-18 secretion in human monocytes, a pathway which is engaged prior to CIP onset, with IL-18 selectively elevated in the plasma of patients who subsequently develop CIP. Myeloid-restricted ablation of

Indexed as

clinico-genomicsimmune related adverse eventsImmunotherapyinflammasomepneumonitis

Identifiers

PMID42433291
PMCPMC13347256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.